第二阶段
我们是谁
结直肠癌肝转移免疫疗法组合平台研究
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
阿美单抗与抗 PD-1 单克隆抗体和 FOLFIRI 联合用于 RAS 野生型晚期结直肠癌患者的研究
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer
A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver
联合免疫疗法方案的 I/II 期研究：治疗转移性结直肠癌 (mCRC) 的联合免疫疗法方案：SX-682、TriAdeno 疫苗、雷替凡利单抗和 IL-15 激动剂 N-803 (STAR15)
